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Abstract
Background—Fragile X premutation carriers are at increased risk for fragile X-associated 
tremor ataxia syndrome (FXTAS), but to date we know little about prediction of onset and rate of 
progression, and even less about treatment of this neurodegenerative disease. Thus, longitudinal 
study of carriers, and identification of potential biomarkers and prodromal states, is essential. 
Here, we present results of baseline assessments from an ongoing longitudinal project.
Methods—The cohort consisted of 73 males, 48 with the fragile X mental retardation 1 (FMR1) 
premutation (55–200 cytosine-cytosine-guanine, CGG repeats) and 25 well-matched controls (< 
40 repeats) between 40 and 75 years. At enrollment, none met criteria for FXTAS or had any 
clinically-significant tremor or ataxia by blinded neurological examination. The battery consisted 
of measures of visual memory, spatial working memory, response inhibition, motor speed and 
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control, planning and problem solving, sustained attention, and a standardized movement disorder 
evaluation.
Results—Contrary to expectations, there were no significant differences between premutation 
carriers and controls on any measure of executive function. However, premutation carriers had 
significantly longer manual movement and reaction times than controls, and the significant 
interaction between CGG repeat and age revealed the slowest movement times among older 
carriers with higher CGG repeat alleles. A subset of premutation carriers had marginally lower 
scores on the ataxia evaluation, and they performed no differently from controls on the 
parkinsonism assessment.
Conclusion—Early-developing cerebellar or fronto-motor tract white matter changes, previously 
documented in MRI studies, may underlie motor slowing that occurs before clinically observable 
neurological symptoms.
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Introduction
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative 
disorder that affects many carriers of the fragile X premutation. The FXTAS phenotype is 
characterized by progressive gait ataxia, intention tremor, parkinsonism, dementia, 
autonomic dysfunction, and peripheral neuropathy.1 FXTAS demonstrates only partial 
penetrance; although larger studies are needed, one important survey suggested that 47% of 
males with the fragile X premutation will develop FXTAS by the 8th decade of life.2 Fragile 
X carriers harbor a trinucleotide expansion of the fragile X mental retardation 1 (FMR1) 
gene between 55 and 200 CGG repeats. There are two known molecular mechanisms of this 
disorder: 1) a toxic gain of function of the expanded CGG-repeat FMR1 mRNA, which 
results in the sequestration of the CGG-binding proteins contributing to inclusion formations 
in neurons and astrocytes; and (2) CGG repeat-associated non-AUG-initiated (RAN) 
translation, which generates a peptide toxic to cells.3 Also, recent studies have shed light on 
additional potential mechanisms of pathogenesis such as the antisense transcript ASFMR1 
and mitochondrial dysfunction.4, 5 While the clinical, neuropathological and 
neuroanatomical features of FXTAS have been described extensively, the risk and protective 
factors for development of the disease are largely unknown. Currently there are no 
empirically validated treatments for FXTAS.
In their 2014 review of the cognitive phenotype of premutation carriers, Grigsby and 
colleagues stated that individuals with FXTAS show cognitive impairments in areas of 
executive functioning, working memory, and information processing, and Brega and 
Grigsby6, 7 referred to FXTAS as a “dysexecutive syndrome.” The cognitive phenotype of 
FXTAS appears to be consistent with fronto-cerebellar dysfunction and disease in a variety 
of white matter tracts, as variability in cognitive performance has been correlated with 
diffusion tensor imaging alterations in white matter, which are in turn related to FMR1 
measures taken from blood samples in these carriers.1, 8, 9
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The neuropsychological/cognitive abnormalities experienced by premutation carriers 
without FXTAS (or those who have not yet developed neurological symptoms; PFX-), on the 
other hand, are generally much more mild and usually below clinical significance, often 
requiring especially sensitive cognitive and brain measurements to detect effects and 
associations with FMR1 molecular measures.8–19 It is notable that in some studies a 
subgroup of premutation carriers who do not yet meet diagnostic criteria for FXTAS exhibit 
subtle weaknesses in executive function and frontal-executive motor control that are very 
similar to the more pervasive and robust deficits in patients with the fully developed 
syndrome.1 These observations raise a critical question whether milder EF weaknesses are in 
fact early markers of later frank neurodegeneration in FXTAS disease progression. An 
understanding of the key early markers and the actual pattern of emergence of FXTAS 
symptoms related to neuropsychological, neurological and brain changes should provide a 
foundation for monitoring during prodromal stages, earlier intervention and treatment, and 
later tracking of progression or stabilization.
The use of longitudinal studies is likely to be essential for evaluating whether such deficits 
are early signs of FXTAS and for understanding their progression over time. For example, 
longitudinal studies of preclinical Alzheimer’s disease (AD) have utilized the Cambridge 
Neuropsychological Test Automated Battery (CANTAB) as a neuropsychological marker, 
detecting dysfunction characteristic of probable AD diagnosis. In participants with 
‘questionable dementia’ (QD) the baseline performance on CANTAB Paired Associates 
Learning (PAL) correlated with global cognitive decline over 8 months, and PAL scores 
allowed detection of a sub-group of QD participants who performed at the same range as 
diagnosed AD participants.20 Thirty-two months after the first assessment, 11 out of 43 QD 
participants were ‘converters’ who met criteria for probable AD. Performance on the PAL 
combined with the Graded Naming Test created a model that predicted diagnosis of probable 
AD with 100% accuracy for their sample of 40 participants.21 The predictive validity of the 
CANTAB in longitudinal studies of preclinical Alzheimer’s suggests that this battery may be 
a promising instrument for identifying at-risk carriers and monitoring early 
neuropsychological signs of pre-FXTAS progression.
Here, we present results from a baseline (time 1) assessment in the first longitudinal 
neuropsychological and neurological study of PFX- men and controls. We hypothesized that 
the PFX- group would demonstrate age-related deficits compared to matched controls on 
tasks involving visuo-spatial working memory, hippocampal-mediated memory recall, 
inhibition, and problem-solving linked to executive function. As FXTAS is predominantly a 
movement disorder, we also assessed various aspects of manual motor control and speed, 
and ataxia. We expected CGG repeat- and FMR1 mRNA-dependent effects on performance, 
such that individuals with both higher CGG repeats and older age would be most affected.
Method
Participants
The sample consisted of 77 males, 52 with the FMR1 premutation (55–200 FMR1 CGG 
repeats) and 25 healthy controls (< 40 CGG repeats) between the ages of 40 and 75 years. 
After enrollment and neurological exam review of all participants, 4 carriers were found to 
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meet criteria for FXTAS and were excluded from analyses. Premutation and control groups 
did not differ significantly on age, IQ, education level, ethnicity/race, marital status or 
income (Table 1). The data reported here are from the first time point in a longitudinal 
project examining brain, neuropsychological and genetic markers of neurodegeneration in 
FMR1 premutation male carriers. The project protocol was approved by the Institutional 
Review Board at UC Davis and all participants provided signed consent. Participants in the 
premutation group were recruited from over 1200 extended pedigrees of probands with 
fragile X-associated disorders seen for research or clinical care, from flyers posted through 
the National Fragile X Foundation contact list, and from referrals by other clinical 
researchers focused on fragile X-associated disorders in the U.S. and Canada. None were 
ascertained based on clinical information. Participants in the control group were recruited 
from the local community of Sacramento, California, primarily through community and 
University-based flyers and from announcements at a variety of local clubs and 
organizations.
Exclusion criteria included: acute renal, liver, or cardiac medical conditions; history of 
significant head trauma; substance abuse or dependence; use of medicine that impacts 
cerebral blood flow, such as beta blockers (due to effects on functional brain imaging aspects 
of the larger project); presence of metal implants of any kind which would preclude MRI; 
and non-English speaking. Finally, potential participants were excluded during screening if 
they had a history of tremor, ataxia or any other clear movement disorder symptom. (As 
mentioned previously, 4 carriers “passed” screening but were later found to have emerging 
or definite FXTAS symptoms and were excluded). This last exclusion was in place to allow 
the study to focus on the conversion to FXTAS, rather than on participants who already 
manifest the disorder. Only participants rated at FXTAS Stage 0 (no signs) or 1 (equivocal 
signs) based on the blinded neurological exam were allowed into the study and analyses.
Materials and Procedure
The Cambridge Neuropsychological Test Automated Battery (CANTAB; Cambridge 
Cognition, Cambridge, UK) is a touchscreen computer-administered battery providing a 
highly standardized and well-validated set of cognitive tests with excellent test-retest 
reliability. A forced randomization table was used to counterbalance the order of CANTAB 
test administrations across participants.
Memory
CANTAB Paired Associates Learning (PAL): This task assesses hippocampal-mediated 
visual memory recall and is sensitive to changes in medial temporal lobe functioning.22 This 
measure was found to be the best for predicting ‘questionable dementia’ participants who 
converted to probable Alzheimer’s disease in a longitudinal study of neuropsychological 
markers in preclinical Alzheimer’s disease.21
CANTAB Spatial Working Memory (SWM): In this task several boxes appear distributed 
around the screen and one of them contains a hidden token within. Participants must search 
through the boxes until the token is found. An error is made if the participant revisits a box 
where he found a token previously, or if he revisits an empty box that he already clicked on 
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earlier in the same search. This test is sensitive to prefrontal and executive dysfunction.23, 24 
Between errors – the number of times the participant revisits a box where he found a token 
previously – was the chosen dependent variable.
Response Inhibition
CANTAB Stop Signal Task (SST): SST is a measure of response inhibition. Arrows appear 
on the screen and the participant must tap the correct button corresponding to the direction 
the arrow is pointing, left or right. If the auditory beep signal is heard the participant should 
withhold his response and refrain from button pressing. The task uses a staircase design for 
the stop signal delay, allowing the task to adapt to the performance of the participant and 
narrow in on the 50% success rate for inhibition. Mean stop signal reaction time during the 
last half of testing was chosen as the dependent variable.
Motor Speed and Control
CANTAB Reaction Time (RTI): This task contains two variations, simple reaction time 
(SRT) and 5-choice reaction time (CRT). Both versions of the task involve cognitive 
constructs of vigilance, inhibitory control, and manual visual-motor speed. SRT measures 
the participant’s ability to quickly release his first finger from its resting position and 
accurately touch a bright circle stimulus as soon as it appears in a single, predictable 
location. Using the same resting position, CRT measures response to a stimulus that appears 
unpredictably in any one of five locations. We chose to examine CRT based on results of a 
previous study involving patients with Parkinson disease; while patients with parkinsonism 
were slower to initiate and carry out responses than control participants on both SRT and 
CRT, the difference was greater for CRT.25 Furthermore, the CRT taps visuospatial attention, 
and in previous studies we have found both impairments in reaction time in numerical 
visuospatial tasks26 and reduced right temporal-parietal junction activation associated with 
temporal processing in premutation carriers.27
Purdue Pegboard Test (Lafayette Instrument, Lafayette, IN): This classic timed test 
measures gross movements of hands, fingers and arms, and fingertip dexterity, involving 
rapid placement of metal pegs into a series of holes. For this study, participants completed 
one trial each for the left hand, right hand, and both hands together.
Behavioral Dyscontrol Scale-2 (BDS-2).28: The BDS-2 is a 9-item, 19-point scale adapted 
from the work of A.R. Luria. It is a valid and reliable measure of the capacity for behavioral 
self-regulation involving intentional control of motor behavior. In addition, it has been 
documented to be sensitive to involvement in premutation carriers in prior studies. 1, 15
Planning and Problem Solving
CANTAB One Touch Stockings (OTS): This subtest excercises the participant’s abilities 
of planning and problem solving, cognitive constructs related to executive function and 
mediated by prefrontal cortex activity.29 First the participant must move “billiard balls” in a 
lower picture to match the target pattern in an upper display. Balls toward the bottom of the 
stocking cannot be moved until the one above them is relocated. In the testing portion, 
participants are asked to work out mentally the number of moves required to solve the 
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problem in their head and select a number accordingly. The dependent variable examined in 
this task was number of problems solved on first choice.
Sustained Visual Attention
CANTAB Rapid Visual Processing (RVP): This task requires sustained attention, serves as 
a measure of general performance, and is sensitive to dysfunction in the parietal and frontal 
lobes of the brain. In RVP participants must attempt to detect three different target sequences 
of digits. The display shows a central box where digits (2–9) appear one at a time and 
change rapidly, at the rate of 100 digits per minute. When the participant recognizes a target 
sequence, he presses a button at the bottom of the screen. We selected A’ signal detection as 
the dependent variable. RVP A′ has been shown to be sensitive to both neurological damage 
(e.g., in Alzheimer’s disease), and pharmacological manipulation, such as by the cholinergic 
agonist, nicotine.22
Motor Examination—The Movement Disorder Society-Unified Parkinson Disease Rating 
Scale (MDS-UPDRS) is a validated widely used instrument that covers the relevant domains 
of Parkinson’s disease and is used to follow its longitudinal course. The bradykinesia 
subscale of the MDS-UPDRS motor examination also was examined and consisted of the 
following five items: finger taps (left and right), hand movement (left and right), rapid 
alternate movements of hands (right and left), leg agility (right and left), and body 
bradykinesia and hypokinesia.
General Intelligence—The Wechsler Adult Intelligence Scale, Third Edition (WAIS-
III33) was used to measure overall cognitive ability.
Molecular Measures—Genomic DNA was isolated from 3ml of peripheral blood 
leukocytes using standard method (Qiagen, Valencia, CA). CGG sizing was determined 
using a combination of PCR and Southern Blot as previously described.34, 35 Total RNA was 
isolated from 3ml of whole blood, collected either in Tempus or PaXgene tubes, according 
to the manufacturer’s instructions (Applied Biosystems, Foster City, CA and Qiagen, 
Valencia, CA, respectively). Quantifications of FMR1 mRNA expression levels were 
performed using a 7900 Sequence detector (Applied Biosystems, Foster City, CA) using 
specific primers and probes as previously reported.36
Statistical Analyses—In the first set of analyses, we carried out statistical comparisons 
for each dependent variable of interest to quantify differences between PFX- and controls 
(Table 2). The second set of analyses examined the association between the outcomes and 
age, FMR1 CGG repeat size and FMR1 mRNA level. For measures with adequate range and 
distribution (all but UPDRS and ICARS) linear and quadratic regression models were used 
that included age, repeat size/mRNA, and the interaction between age and repeat size/mRNA 
as predictors. In addition, we examined whether use of psychotropic medication influenced 
the results of the analyses. Of the 48 participants in the premutation group, 15 (31.2%) 
reported taking psychotropic medication, as did 3 out of the 25 control participants (12.0%). 
Table 3 presents the parameter estimates and model information from the final model for 
each variable.
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Results
Visual memory
In the Paired Associates Learning (PAL) test, the analyses for Total Errors (Adjusted) 
indicated that observed differences in task performance between PFX- and controls were not 
statistically significant. The best model from regression analyses included both linear and 
quadratic terms of CGG repeat size. Parameter estimates were statistically significant for 
both terms, indicating a nonlinear relation across the CGG repeat span in the form of an 
increase in the total errors for those with mid-length expansions, followed by a decrease.
Spatial working memory
Similarly, analyses for between errors made during SWM yielded a nonsignificant 
comparison between groups. The best model was one that included linear components of age 
and CGG. This model indicated that the errors increased linearly with age but were not 
associated with CGG.
Response inhibition
No significant differences were found between groups for the SST reaction time measure. 
Neither linear nor quadratic regression analyses indicated a relation to age or CGG repeat 
size.
Planning and problem solving
Analyses regarding problems solved on first choice within the OTS test showed no 
significant differences between PFX- and controls. Score on this measure was linearly and 
negatively related to age. Neither a higher-order age function nor CGG were statistically 
associated with performance on the test.
Sustained visual attention
The groups did not significantly differ on performance of A’ signal detection within the RVP 
test. A similar pattern to OTS was found for the RVP A’ signal detection measure, namely 
this variable was linearly and negatively related to age.
Motor control and speed
For the motor tests, analyses yielded significant differences for both the CANTAB reaction 
time and movement time measures, and for the Purdue Pegboard. Between-group 
comparisons indicated that PFX- were statistically slower in manual reaction time and 
movement time, and they placed fewer Purdue pegs than controls. No significant group 
differences were found for the BDS-2. The best model for RTI movement time was one that 
included linear terms for age and CGG repeats, as well as their interaction, which indicated 
that increased movement time was observed primarily in older carriers with larger CGG 
repeat size (Figure 1). Unlike the previously discussed variables, the total explained variance 
by this model was moderate (R2 = .23). For RTI reaction time, a similar model with linear 
trends for age and CGG was also best. Likewise on Purdue Pegboard there were linear 
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effects of both age and CGG. However, no significant interaction of CGG and age was 
observed on these variables.
Neurological examination
Although carriers with FXTAS were excluded from the study, given the results of slowed 
manual reaction and movement times, we were interested to examine whether any 
participants had even subtle or equivocal tremor or bradykinesia by neurological exam that 
might explain the findings. Indeed, none of the carriers or controls had any signs of 
dominant or non-dominant hand tremor according to the UPDRS37 or the finger-to-nose test 
of the ICARS32, and there was no significant group difference on the UPDRS bradykinesia 
subscale (p=.34). Group comparisons revealed skewed data with few subjects in either group 
with elevated scores, necessitating non-parametric (Mann-Whitney) tests for the UPDRS and 
ICARS. Results showed no differences on the UPDRS, and a statistically significant, but 
modest elevation on the ICARS for carriers compared to controls (see Table 2).
FMR1 mRNA (in place of CGG repeat length in the above regression models) had no 
significant associations with the dependent variables of interest, either alone or in interaction 
with age, except for with Purdue Pegboard (higher mRNA associated with worse 
performance; t=−2.42, p = .018).
Discussion
Fragile X premutation carriers are confronted by many health risks as they age, and often 
express concern and questions about whether they will develop FXTAS, how soon, and how 
quickly it will progress. Although limited evidence suggests that higher CGG repeat size is 
associated with an earlier age of FXTAS onset and age of death,38 little is known about risk 
and protective factors, and there is no consensus on early clinical or biological markers for 
onset or progression. These markers may turn out to be key brain imaging signs, 
neurological or neuropsychological changes, specific molecular markers, or a combination 
of the above. What is clear is that longitudinal studies are essential to identify such markers 
and their relative prognostic value. Here, we presented baseline neuropsychological and 
neurological data from a well-characterized cohort of premutation carriers at risk for FXTAS 
using a widely-validated computer-based test battery.
Based on prior published studies highlighting executive function in carriers with and without 
FXTAS, we hypothesized significant weaknesses in these areas, and predicted that they 
would be associated with older age and higher CGG repeat length. These hypotheses were 
not confirmed. In fact, carriers were no worse than controls in several executive function 
domains including response inhibition, sustained visual attention, frontal-mediated problem 
solving, and visual spatial memory. Also the lack of differences on the BDS-2, involving 
executive control of movement was surprising, given prior literature and the instrument’s 
clear sensitivity to FXTAS EF deficits. One possibility is that deficits in these domains may 
occur at a later stage or only in older carriers, as they approach typical age of FXTAS onset. 
However, in this cohort, a lack of interaction of CGG size and age for these metrics does not 
support this interpretation. The lack of prominent effects on the key EF domains in our 
cohort does not necessarily exclude the possibility that deficits in these areas may coincide 
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with, or even pre-date FXTAS onset. The inconsistency across published studies regarding 
EF deficits in PFX- appears related to cohort differences and/or subtle differences in the tests 
used to tap these domains. Subtle weaknesses in hippocampus-mediated visual memory do 
appear to be present in carriers with mid-length CGG alleles, a finding that may be 
consistent with alterations in hippocampus, and co-activation of the hippocampus and frontal 
regions in memory recall and encoding tasks.9, 39 To clarify the prodrome, we and others 
will need to examine the trajectories of cognitive and motor functions over time in carriers 
as they transition into and fully manifest the disorder.
The most robust finding of the present study was the slowing of manual motor reaction and 
movement times while reaching for a target and while performing a manual dexterity task in 
carriers relative to controls that were correlated with both higher CGG repeat length and 
older age. This slowing could not be explained by any observable tremor or bradykinesia by 
blinded neurological exam by an experienced movement disorder specialist. One 
interpretation of this finding is that early-developing cerebellar or fronto-cerebellar tract 
changes in carriers 8, 40 underlie the motor slowing seen in the RTI tasks. These changes 
could be occurring before the appearance of intention tremor in high risk individuals. This 
interpretation is consistent with several studies of upper limb movement in cerebellar ataxia 
neurodegenerative diseases. For example, an early comparative study of motor reaction time 
in Parkinson’s, Huntington’s, and cerebellar diseases showed that patients with cerebellar 
disease had slower movement times compared to the patients with Parkinson’s disease and 
Huntington’s disease, whose times did not differ.41 Day and colleagues42 examined spatial 
and temporal characteristics of free reaching movements of the arm in 17 patients with 
ataxic syndromes due to disease of the cerebellum. Participants were required to reach out 
and touch a visually presented target (similar to the CRT test in our study) either in the dark 
or with the target and their finger visible. Overall, patients had prolonged reaction and 
reaching movement times, and the spatial paths described by their fingertips were more 
circuitous. The authors suggested that these spatial errors and delays arise because the 
cerebellum normally contributes either directly or indirectly to preparatory motor processes 
which compute the pattern of muscle activity required to launch the limb accurately towards 
a target. This abnormality would have implications for both upper limb movement, but also 
leg movements that would impact gait and balance that is also seriously impacted in FXTAS. 
Given that movement problems also typically precede cognitive decline in Parkinson’s 
disease, it would be reasonable to explore the potential impact of basal ganglia changes in 
the pathogenesis of FXTAS, as it is known that the characteristic inclusion formations do 
occur in this region43. The forthcoming longitudinal data from our project, including MRI 
delineating brain changes will determine the specificity and neural basis of motor slowing in 
prodromal FXTAS, in particular the possibility that subtle reaching movement abnormalities 
precede more obvious and clinically significant neurological problems.
This study was limited by a smaller control group; it was necessary to devote limited 
resources to the recruitment, travel, and imaging of carriers. Also, the molecular markers 
were taken from blood samples, which provide an indirect estimate of these markers in 
brain. It also would have also been advantageous to study associations between measures of 
mitochondrial function and RAN translation, as these have been implicated in the FXTAS 
pathogenesis. In addition, individuals participating in the study were very high functioning, 
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primarily Caucasian, and well educated. Thus the results may not generalize to the full 
population of premutation carriers. We focused on males due to the much higher risk of 
FXTAS in males in this X-linked condition, and as such, these results may not generalize to 
women.
The results of the longitudinal project may provide information about the early markers of 
neurodegeneration that will aid in identifying carriers most in need of preventive care and 
treatment as these interventions become available. This research also may identify important 
measures for tracking response to interventions in the future. The analysis of combined 
molecular, brain, neurological and neuropsychological data, as well as a variety of indicators 
of risk and resilience across mid to late adulthood is essential for understanding the 
pathogenesis and treatment of FXTAS.
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Figure 1. Manual movement time and age
The association between age and CANTAB 5-choice manual movement time in fragile X 
premutation carriers asymptomatic for FXTAS and healthy controls. This test involves 
resting the dominant hand forefinger on a rectangle at the bottom of a tablet screen until one 
of 5 locations is illuminated, at which time the participant touches the target as quickly as 
possible. Linear regression modeling showed a significant interaction between FMR1 CGG 
length and age, demonstrating that older carriers with high CGG alleles had the slowest 
movement times.
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Table 3
Parameter estimates from regression analyses examining relation between age/CGG repeat length and 
dependent variables.
Estimate (SE) t-value p R2
Memory
 PAL total errors .064
  CGG .716 (.334) 2.14 .035
  CGG2 −.005 (.002) −2.18 .032
 SWM between errors
  age .645 (.291) 2.22 .029 .085
  CGG .100 (.081) 1.24 .221
Response Inhibition
 SST reaction time .030
  age .798 (.758) 1.05 .296
  CGG .217 (.211) 1.03 .307
Motor Control and Speed
 CRT movement time .225
  age −1.417 (2.226) −0.64 .527
  CGG −3.248 (1.819) −1.79 .079
  age*CGG 0.069 (.032) 2.12 .038
 CRT reaction time .130
  age .668 (.528) 1.27 .210
  CGG .435 (.147) 2.96 .004
 BDS-2 .109
  age -.089 (.030) −2.91 .005
  CGG -.003 (.008) −0.34 .733
 Purdue Pegboard .309
  age -.221 (.060) −3.70 .001
  CGG -.068 (.016) −4.12 .001
Planning and Problem Solving
 OTS problems solved .069
  age -.066 (.029) −2.30 .025
Sustained Visual Attention
 RVP A′ signal detection .116
  age -.001 (.001) −2.18 .033
  Medication -.025 (.015) −1.97 .053
Abbreviations: PAL, Paired Associates Learning; SWM, Spatial Working Memory; SST, Stop Signal Task; CRT, Choice Reaction Time; OTS, One-
Touch Stockings; RVP, Rapid Visual Processing
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